Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 23, 2009, Pages 6588-6590

  Canzoneri, Joshua C ^a   Chen, Po C ^a   Oyelere, Adegboyega K ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

HDAC; Histone deacetylase inhibition; NLS

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; VORINOSTAT;

ARTICLE; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL;

DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MOLECULAR CONFORMATION; NUCLEAR LOCALIZATION SIGNALS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71749084293     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.028     Document Type: Article

References (26)

1. Marks P.A. Oncogene 26 (2007) 1351
2. FDA approves vorinostat (Zolinza) for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm094952.htm.
3. Marson C.M., Mahadevan T., Dines J., Segmany S., Morrell J.M., Alao J.P., Joel S.P., Vigushin D.M., and Coombes R.C. Bioorg. Med. Chem. Lett. 17 (2007) 136
4. Moradei O., Maroun C.R., Paquin I., and Vaisburg A. Curr. Med. Chem.: Anti-Cancer Agents 5 (2005) 529
5. Hildmann C., and Riester D. Appl. Microbiol. Biotechnol. 75 (2007) 487
6. Marks P., Rifkind R., Richon V., Breslow R., Miller T., and Kelly W. Nat. Rev. Cancer 1 (2001) 194
7. Johnstone R.W., and Licht J.D. Cancer Cell 4 (2003) 13
8. Carey N., and Thangue N. Curr. Opin. Pharmacol. 6 (2006) 369
9. Estiu G., Greenberg E., Harrison C., Kwiatkowski N., Mazitschek R., Bradner J., and Wiest O. J. Med. Chem. 51 (2008) 2898
10. Hkan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S., Carey N., Finn P., Collins N., Tumber A., Ritchie J., Jensen P., Lichenstein H., and Sehested M. Biochem. J. 409 (2008) 581
11. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097
12. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4389
13. Carew J.S., Francis J.G., and Nawrocki S.T. Cancer Lett. 269 (2008) 7
14. Bieliauskas A.V., and Pflum M.K.H. Chem. Soc. Rev. 37 (2008) 1402
15. Chen P., Patil V., Guerrant W., Green P., and Oyelere A. Bioorg. Med. Chem. 16 (2008) 4839
16. Oyelere A., Chen P., Guerrant W., Mwakwari S., Hood R., Zhnag Y., and Fan Y. J. Med. Chem. 52 (2009) 456
17. Bolden J.E., Part M.J., and Johnstone R.W. Nat. Rev. Drug Disc. 5 (2006) 769
18. Johnstone R.W. Nat. Rev. Drug Disc. 1 (2002) 287
19. Tkachenko A.G., Xie H., Coleman D., Glomm W., Ryan J., Anderson M.F., Franzen S., and Feldheim D.L. J. Am. Chem. Soc. 125 (2003) 4700
20. Oyelere A.K., Chen P.C., Huang X., El-sayed I.H., and El-sayed M.A. Bioconjugate Chem. 18 (2007) 1490
21. Kalderon D., Richardson W.D., Markham A.F., and Smith A.E. Nature (London) 311 (1984) 33
22. De la Furente J.M., and Berry C.C. Bioconjugate Chem. 16 (2005) 1176
23. Rostovtsev V.V., Green L.G., Fokin V.V., and Sharpless K.B. Angew. Chem., Int. Ed. 41 (2002) 2596
24. Tornoe C.W., Christensen C., and Meldal M.J. Org. Chem. 67 (2002) 3057
25. ® International, Plymouth Meeting, PA, 2005.
26. Loudet A., and Burgess K. Chem. Rev. 107 (2007) 4891